Showing 3561-3570 of 19355 results for "".
Personalizing First-Line Therapy for CLL
https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/Experts explore first-line therapy selection in CLL, including biomarker testing, time-limited vs continuous regimens, safety profiles, and recent trial data.Sustained Antidepressant and Sleep Benefits With Adjunctive Seltorexant in MDD: Double-Blind and Long-Term Extension Data From the MD3001 Trial
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/sustained-antidepressant-and-sleep-benefits-with-adjunctive-seltorexant-in-mdd-double-blind-and-long-term-extension-data-from-the-md3001-trial/36555/Review Phase 3 MD3001 trial data on adjunctive seltorexant in MDD with insomnia, including double-blind efficacy and 1-year extension safety outcomes.Oh, the Hats You'll Wear! The Many Modalities of Pediatric Obesity Management
https://reachmd.com/programs/cme/oh-the-hats-youll-wear-the-many-modalities-of-pediatric-obesity-management/39966/On-demand webcast of expert faculty presentation on the diagnosis and management of obesity for pediatric patients, including communication and patient-centered care strategies to improve health outcomes.From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
https://reachmd.com/programs/cme/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/Explore how bispecific antibodies are moving earlier in the treatment paradigm of multiple myeloma, supported by pivotal data showing improved patient outcomes.SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
https://reachmd.com/clinical-practice/cardiology/scout-hcm-mavacamten-in-adolescents-with-symptomatic-obstructive-hypertrophic-cardiomyopathy/56460/Explore phase 3 SCOUT-HCM findings on mavacamten from ACC 2026, including study design, efficacy outcomes, and implications for managing adolescents with oHCM.Molecular Profiling as a Cornerstone of Precision AML Therapy
https://reachmd.com/programs/cme/molecular-profiling-as-a-cornerstone-of-precision-aml-therapy/36178/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.A Clinician's Guide to the ACIP Travel Vaccination Recommendations
https://reachmd.com/programs/vaccination/a-clinicians-guide-to-the-acip-travel-vaccination-recommendations/26483/Get ready to integrate the latest ACIP updates into practice to improve patient care and public health outcomes with this essential recap.Double-Class Refractory CLL in Community Practice: Current and Future Management
https://reachmd.com/programs/cme/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/Explore expert-guided strategies for managing double-class-refractory CLL, including BTK resistance, treatment sequencing, and emerging therapeutic options.Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
https://reachmd.com/clinical-practice/oncology-hematology/patient-reported-outcomes-from-the-phase-3-keynote-689-trial-of-adding-perioperative-pembrolizumab-to-standard-of-care-in-resectable-locally-advanced-hnscc/39777/In KEYNOTE-689, patient-reported outcomes including HRQOL remained stable vs baseline with perioperative pembrolizumab in resectable locally advanced HNSCC.Alloimmune Thrombocytopenia in the Fetus and Newborn
https://reachmd.com/programs/cme/alloimmune-thrombocytopenia-in-the-fetus-and-newborn/13909/In severe cases, FNAIT can lead to fetal intracranial hemorrhage. How can you lower risks for your patients facing this uncommon disorder?